- Home
- ONDS vs BRNS Comparison
ONDS vs BRNS Comparison
Compare ONDS & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONDS | BRNS |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 24.1M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ONDS | BRNS |
|---|---|---|
| Price | $9.07 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $19.83 | $4.00 |
| AVG Volume (30 Days) | ★ 69.8M | 20.3K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $50,731,000.00 | N/A |
| Revenue This Year | $662.14 | N/A |
| Revenue Next Year | $76.37 | N/A |
| P/E Ratio | $16.46 | ★ N/A |
| Revenue Growth | ★ 605.31 | N/A |
| 52 Week Low | $1.36 | $0.51 |
| 52 Week High | $15.28 | $2.91 |
Technical Indicators
Market Signals| Indicator | ONDS | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 47.01 |
| Support Level | $8.43 | $0.65 |
| Resistance Level | $11.87 | $0.75 |
| Average True Range (ATR) | 0.89 | 0.05 |
| MACD | -0.26 | -0.00 |
| Stochastic Oscillator | 6.10 | 22.33 |
Price Performance
Historical ComparisonAbout ONDS Ondas Holdings Inc.
Ondas Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system. Geographically, the company operates in Israel, Germany, United Arab Emirates, United States, and Other Countries. It derives maximum revenue from Israel.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.